News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
711,381 Results
Type
Article (42168)
Company Profile (436)
Press Release (668777)
Section
Business (208684)
Career Advice (2021)
Deals (36002)
Drug Delivery (103)
Drug Development (83543)
Employer Resources (173)
FDA (16399)
Job Trends (15081)
News (352664)
Policy (33046)
Tag
2024 BioCapital Digital (10)
2024 BioForest Digital (2)
2024 BioForest Standard (1)
2024 BioMidwest Digital (9)
2024 BioMidwest Standard (1)
2024 Bio NC Digital (8)
2024 Bio NC Standard (2)
2024 Biotech Bay Standard (18)
2024 Biotech Beach Digital (10)
2024 Biotech Beach Standard (5)
2024 Genetown Digital (8)
2024 Genetown Standard (10)
2024 Lone Star Bio Digital (8)
2024 Pharm Country Digital (7)
2024 Pharm Country Standard (6)
2025 BioForest Digital (4)
2025 Lone Star Bio Digital (8)
2026 BioCapital Standard (1)
2026 BioMidwest Elite (2)
2026 Biotech Bay Elite (1)
2026 Biotech Bay Standard (1)
2026 Biotech Beach Elite (2)
2026 Genetown Elite (3)
2026 Pharm Country Elite (1)
2026 Pharm Country Standard (1)
Academia (2637)
Accelerated approval (3)
Adcomms (24)
Allergies (80)
Alliances (50892)
ALS (86)
Alzheimer's disease (1391)
Antibody-drug conjugate (ADC) (120)
Approvals (16380)
Artificial intelligence (240)
Autoimmune disease (16)
Automation (14)
Bankruptcy (371)
Best Places to Work (11841)
BIOSECURE Act (18)
Biosimilars (100)
Biotechnology (330)
Bladder cancer (61)
Brain cancer (24)
Breast cancer (250)
Cancer (1987)
Cardiovascular disease (157)
Career advice (1686)
Career pathing (29)
CAR-T (146)
Cell therapy (413)
Cervical cancer (16)
Clinical research (67412)
Collaboration (793)
Compensation (450)
Complete response letters (23)
COVID-19 (2639)
CRISPR (39)
C-suite (210)
Cystic fibrosis (103)
Data (1887)
Decentralized trials (2)
Denatured (25)
Depression (44)
Diabetes (246)
Diagnostics (6381)
Digital health (18)
Diversity (8)
Diversity, equity & inclusion (44)
Drug discovery (114)
Drug pricing (104)
Drug shortages (26)
Duchenne muscular dystrophy (87)
Earnings (87276)
Editorial (35)
Employer branding (21)
Employer resources (147)
Events (115059)
Executive appointments (642)
FDA (17488)
Featured Employer (55)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (8)
Funding (712)
Gene editing (102)
Generative AI (19)
Gene therapy (294)
GLP-1 (714)
Government (4462)
Grass and pollen (4)
Guidances (48)
Healthcare (19140)
Huntington's disease (23)
IgA nephropathy (24)
Immunology and inflammation (111)
Indications (27)
Infectious disease (2767)
Inflammatory bowel disease (137)
Inflation Reduction Act (11)
Influenza (46)
Intellectual property (83)
Interviews (311)
IPO (16766)
IRA (43)
Job creations (3699)
Job search strategy (1434)
Kidney cancer (9)
Labor market (33)
Layoffs (475)
Leadership (16)
Legal (7976)
Liver cancer (71)
Lung cancer (284)
Lymphoma (130)
Machine learning (2)
Management (58)
Manufacturing (272)
MASH (61)
Medical device (13459)
Medtech (13464)
Mergers & acquisitions (19688)
Metabolic disorders (651)
Multiple sclerosis (69)
NASH (19)
Neurodegenerative disease (85)
Neuropsychiatric disorders (30)
Neuroscience (1883)
NextGen: Class of 2025 (6757)
Non-profit (4546)
Northern California (2382)
Now hiring (36)
Obesity (356)
Opinion (222)
Ovarian cancer (72)
Pain (79)
Pancreatic cancer (76)
Parkinson's disease (134)
Partnered (18)
Patents (198)
Patient recruitment (91)
Peanut (46)
People (58418)
Pharmaceutical (86)
Pharmacy benefit managers (19)
Phase I (21182)
Phase II (29747)
Phase III (21999)
Pipeline (932)
Podcasts (72)
Policy (114)
Postmarket research (2602)
Preclinical (9030)
Press Release (67)
Prostate cancer (93)
Psychedelics (37)
Radiopharmaceuticals (260)
Rare diseases (371)
Real estate (6008)
Recruiting (66)
Regulatory (22559)
Reports (46)
Research institute (2413)
Resumes & cover letters (351)
Rett syndrome (3)
RNA editing (2)
RSV (37)
Schizophrenia (69)
Series A (128)
Series B (82)
Service/supplier (11)
Sickle cell disease (54)
Southern California (2072)
Special edition (17)
Spinal muscular atrophy (151)
Sponsored (29)
Startups (3757)
State (2)
Stomach cancer (13)
Supply chain (60)
The Weekly (45)
United States (21206)
Vaccines (671)
Venture capitalists (38)
Webinars (13)
Weight loss (243)
Women's health (34)
Worklife (16)
Date
Today (156)
Last 7 days (611)
Last 30 days (2976)
Last 365 days (34800)
2025 (7570)
2024 (36304)
2023 (41020)
2022 (52277)
2021 (56764)
2020 (54925)
2019 (47421)
2018 (35704)
2017 (33034)
2016 (32353)
2015 (38399)
2014 (32190)
2013 (27115)
2012 (29221)
2011 (29868)
2010 (27998)
Location
Africa (735)
Alabama (54)
Alaska (7)
Arizona (229)
Arkansas (14)
Asia (39074)
Australia (6507)
California (5513)
Canada (1854)
China (465)
Colorado (245)
Connecticut (266)
Delaware (125)
Europe (85320)
Florida (802)
Georgia (188)
Idaho (57)
Illinois (500)
India (22)
Indiana (289)
Iowa (10)
Japan (136)
Kansas (102)
Kentucky (24)
Louisiana (8)
Maine (60)
Maryland (835)
Massachusetts (4221)
Michigan (210)
Minnesota (371)
Mississippi (2)
Missouri (76)
Montana (29)
Nebraska (25)
Nevada (56)
New Hampshire (66)
New Jersey (1560)
New Mexico (30)
New York (1574)
North Carolina (968)
North Dakota (7)
Northern California (2382)
Ohio (193)
Oklahoma (14)
Oregon (37)
Pennsylvania (1236)
Puerto Rico (9)
Rhode Island (26)
South America (1108)
South Carolina (17)
South Dakota (1)
Southern California (2072)
Tennessee (92)
Texas (816)
Utah (165)
Virginia (131)
Washington D.C. (59)
Washington State (524)
West Virginia (3)
Wisconsin (49)
711,381 Results for "dmd therapeutics inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Duchenne muscular dystrophy
5 DMD Candidates to Watch in 2025
Riding recent momentum in the Duchenne muscular dystrophy space, Capricor Therapeutics, Wave Life Sciences, Regenxbio and more aim to deliver the next wave of progress with near-term data and regulatory milestones.
January 27, 2025
·
6 min read
·
Kate Goodwin
Press Releases
Precision BioSciences Presents Preclinical Efficacy and Durability Data on PBGENE-DMD for the Treatment of Duchenne Muscular Dystrophy (DMD) at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference
March 19, 2025
·
11 min read
Gene Therapy
Sarepta Shares Crash 22% After Patient on DMD Gene Therapy Elevidys Dies
After a patient taking the Duchenne muscular dystrophy gene therapy Elevydis died of liver injury, Sarepta will update the label to reflect the safety signal.
March 18, 2025
·
2 min read
·
Tristan Manalac
Press Releases
PepGen Announces Update to Phase 2 CONNECT2-EDO51 Study in Patients with DMD
March 5, 2025
·
7 min read
Duchenne muscular dystrophy
Dyne Touts ‘Unprecedented’ Dystrophin Expression in Phase I/II DMD Trial for Exon-Skipping Therapy
The highly anticipated results come as the company makes significant changes to its C-suite. Despite the turnover, Dyne said it is looking toward expedited approval pathways for its DMD treatment.
September 3, 2024
·
3 min read
·
Tristan Manalac
BioCapital
REGENXBIO to Participate in Cantor Fitzgerald’s Virtual DMD and Other Dystrophy Days
REGENXBIO Inc. (Nasdaq: RGNX) today announced it will participate in Cantor Fitzgerald’s Virtual DMD and Other Dystrophy Days on Wednesday, April 3, 2024.
March 27, 2024
·
1 min read
Duchenne Muscular Dystrophy
Déjà Vu for PepGen as FDA Places Hold on DMD Drug
The FDA has put a stop to U.S. initiation of PepGen’s Phase II trial for its Duchene muscular dystrophy treatment. The company faced the same hurdle for an earlier neuromuscular candidiate in 2023.
December 16, 2024
·
2 min read
·
Annalee Armstrong
Press Releases
Roche announces new results from EMBARK demonstrating significant sustained benefits of Elevidys in ambulatory individuals with Duchenne muscular dystrophy (DMD)
January 27, 2025
·
11 min read
Duchenne muscular dystrophy
Regenxbio Gears Up to Challenge Sarepta in DMD as Gene Therapy Advances to Pivotal Studies
Regenxbio is pushing its Duchenne muscular dystrophy gene therapy into pivotal development, with a BLA planned for 2026—potentially posing a threat to Sarepta’s Elevidys.
November 19, 2024
·
2 min read
·
Tristan Manalac
Earnings
Sarepta Halts Development of Next-Gen DMD Drug, Reports Robust Elevidys Sales
The investigational therapy, vesleteplirsen, had been positioned as an updated version of Sarepta’s original exon 51-skipping Duchenne muscular dystrophy drug Exondys 51.
November 7, 2024
·
2 min read
·
Heather McKenzie
1 of 71,139
Next
